Antibody drug discovery: From Idea to Biotherapeutic Molecule

Thesis: M.B.A., Massachusetts Institute of Technology, Sloan School of Management, 2016. === Thesis: S.M., Massachusetts Institute of Technology, Department of Mechanical Engineering, 2016. === Cataloged from PDF version of thesis. === Includes bibliographical references (pages 90-91). === Graybel (...

Full description

Bibliographic Details
Main Author: Davis, Katherine A. D
Other Authors: Retsef Levi and Daniel Whitney.
Format: Others
Language:English
Published: Massachusetts Institute of Technology 2016
Subjects:
Online Access:http://hdl.handle.net/1721.1/104261
id ndltd-MIT-oai-dspace.mit.edu-1721.1-104261
record_format oai_dc
spelling ndltd-MIT-oai-dspace.mit.edu-1721.1-1042612019-05-02T16:16:24Z Antibody drug discovery: From Idea to Biotherapeutic Molecule Davis, Katherine A. D Retsef Levi and Daniel Whitney. Massachusetts Institute of Technology. Department of Mechanical Engineering. Sloan School of Management. Massachusetts Institute of Technology. Department of Mechanical Engineering. Sloan School of Management. Mechanical Engineering. Thesis: M.B.A., Massachusetts Institute of Technology, Sloan School of Management, 2016. Thesis: S.M., Massachusetts Institute of Technology, Department of Mechanical Engineering, 2016. Cataloged from PDF version of thesis. Includes bibliographical references (pages 90-91). Graybel (a fictitious name used for privacy reasons) is a large developer of pharmaceuticals. Graybel's Antibody Protein Engineering Group (APEG) is responsible for early stage drug development of biotherapeutic molecules. Part of this responsibility is delivering high quality molecules while meeting tight deadlines. Across the industry there is constant pressure to decrease timelines, while at the same time the complexity of molecules is increasing. In order to meet this challenge, APEG must be highly adaptable. Unfortunately, unanticipated biology, long project lead times, unpredictable workflows and inadequate workflow tracking systems make it difficult to precisely determine what causes delays. This uncertainty, combined with the inability to quickly pilot changes to process or methodology, makes each potential change both risky and costly. The goal of this project was to provide APEG with two things: the knowledge needed to build a robust workflow tracking system and simulations that would assist in finding root causes of issues and allow for low-cost piloting of potential solutions. Combined, a workflow tracking database and decision tool would greatly reduce the risk associated with implementing changes, allowing APEG to adapt to meet increasingly difficult industry standards. Multiple avenues were used to collect the data needed on APEG's workflow. The primary source of data is interviews, with both management and experienced bench workers. These interviews provided data on workflow paths and estimates for workflow stage durations that could not be found elsewhere. In addition, they provided a way for APEG members to be involved in the project. Additional data was gathered from rudimentary systems that are used to track workflow within some functional groups. This data was then used to create detailed process maps, and simulations. Once validated, simulation results were analyzed and experimented with to determine current bottlenecks, potential future issues and possible fixes for these problems. In addition, a new metric was introduced for quantitatively evaluating the difficulty of a project called the Technology Readiness Level (TRL). Essential project decisions were identified, and recommendations made to track those issues. Bottlenecks were identified through queue analysis. Potential changes to fix these and other issues were piloted to determine effect. Future states, both with and without these changes, were simulated to determine potential problems. From this, causes of current and potential future delay were identified and recommendations developed. Recommendations included staffing changes, cross training, real-life piloting and developing a deeper understanding of certain processes. by Katherine A.D. Davis. M.B.A. S.M. 2016-09-13T19:18:36Z 2016-09-13T19:18:36Z 2016 2016 Thesis http://hdl.handle.net/1721.1/104261 958154275 eng M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission. http://dspace.mit.edu/handle/1721.1/7582 91 pages application/pdf Massachusetts Institute of Technology
collection NDLTD
language English
format Others
sources NDLTD
topic Sloan School of Management.
Mechanical Engineering.
spellingShingle Sloan School of Management.
Mechanical Engineering.
Davis, Katherine A. D
Antibody drug discovery: From Idea to Biotherapeutic Molecule
description Thesis: M.B.A., Massachusetts Institute of Technology, Sloan School of Management, 2016. === Thesis: S.M., Massachusetts Institute of Technology, Department of Mechanical Engineering, 2016. === Cataloged from PDF version of thesis. === Includes bibliographical references (pages 90-91). === Graybel (a fictitious name used for privacy reasons) is a large developer of pharmaceuticals. Graybel's Antibody Protein Engineering Group (APEG) is responsible for early stage drug development of biotherapeutic molecules. Part of this responsibility is delivering high quality molecules while meeting tight deadlines. Across the industry there is constant pressure to decrease timelines, while at the same time the complexity of molecules is increasing. In order to meet this challenge, APEG must be highly adaptable. Unfortunately, unanticipated biology, long project lead times, unpredictable workflows and inadequate workflow tracking systems make it difficult to precisely determine what causes delays. This uncertainty, combined with the inability to quickly pilot changes to process or methodology, makes each potential change both risky and costly. The goal of this project was to provide APEG with two things: the knowledge needed to build a robust workflow tracking system and simulations that would assist in finding root causes of issues and allow for low-cost piloting of potential solutions. Combined, a workflow tracking database and decision tool would greatly reduce the risk associated with implementing changes, allowing APEG to adapt to meet increasingly difficult industry standards. Multiple avenues were used to collect the data needed on APEG's workflow. The primary source of data is interviews, with both management and experienced bench workers. These interviews provided data on workflow paths and estimates for workflow stage durations that could not be found elsewhere. In addition, they provided a way for APEG members to be involved in the project. Additional data was gathered from rudimentary systems that are used to track workflow within some functional groups. This data was then used to create detailed process maps, and simulations. Once validated, simulation results were analyzed and experimented with to determine current bottlenecks, potential future issues and possible fixes for these problems. In addition, a new metric was introduced for quantitatively evaluating the difficulty of a project called the Technology Readiness Level (TRL). Essential project decisions were identified, and recommendations made to track those issues. Bottlenecks were identified through queue analysis. Potential changes to fix these and other issues were piloted to determine effect. Future states, both with and without these changes, were simulated to determine potential problems. From this, causes of current and potential future delay were identified and recommendations developed. Recommendations included staffing changes, cross training, real-life piloting and developing a deeper understanding of certain processes. === by Katherine A.D. Davis. === M.B.A. === S.M.
author2 Retsef Levi and Daniel Whitney.
author_facet Retsef Levi and Daniel Whitney.
Davis, Katherine A. D
author Davis, Katherine A. D
author_sort Davis, Katherine A. D
title Antibody drug discovery: From Idea to Biotherapeutic Molecule
title_short Antibody drug discovery: From Idea to Biotherapeutic Molecule
title_full Antibody drug discovery: From Idea to Biotherapeutic Molecule
title_fullStr Antibody drug discovery: From Idea to Biotherapeutic Molecule
title_full_unstemmed Antibody drug discovery: From Idea to Biotherapeutic Molecule
title_sort antibody drug discovery: from idea to biotherapeutic molecule
publisher Massachusetts Institute of Technology
publishDate 2016
url http://hdl.handle.net/1721.1/104261
work_keys_str_mv AT daviskatherinead antibodydrugdiscoveryfromideatobiotherapeuticmolecule
_version_ 1719037171958022144